Key Points New York City-based Wildcat Capital Management sold 495,606 shares of UroGen Pharma in the third quarter. The shares were worth an estimated $6.79 million. The move marked a full exit from the stock, with Wildcat reporting no shares held as of September 30. These 10 stocks could mint the next wave of millionaires › New York City-based Wildcat Capital Management sold out its entire position in UroGen Pharma Ltd. (NASDAQ:URGN), a move representing a net position change of approximately ...